Therapeutic Discovery Services
Protheragen offers all the solutions for the therapeutic discovery related to the MyD88, such as the development of small molecule inhibitors, monospecific antibodies, siRNA, and mimetic peptides. Our innovation in targeted drug development continues from the early discovery phase through preclinical and IIT support, where we offer hundred percent innovative skills and unique approaches.
Introduction to MyD88
MyD88 holds a key importance as a primary adapter in the interleukin-1 receptor (IL-1R) and the TLR2NH and 3 signalling pathways during an innate immune response. During the activation of any of the two receptors, MyD88 helps to recruit other signaling molecules which allow for the activation of a variety of transcription factors including AP-1 and NF-κB. These transcription factors are responsible for the activation and expression of a variety of pro inflammatory cytokines and immune mediators, thus meaning MyD88 plays a major role in the immune system.
Fig.1 IL-1R family members signalling via the MyD88 adaptor protein in inflammation. (Di Padova, Quesniaux and Ryffel, 2018)Development of MyD88 Inhibitors
MyD88 playing a critical role in innate immunity and inflammatory responses. Studies have shown that aberrant activation of MyD88 is closely associated with various diseases.
Table.1Development of MyD88 Inhibitors in Inflammatory and Autoimmune Diseases. (Liu, Y., et al.,2024)
| Drug | Indication | Mechanism | Phase |
| TAK-242 (Resatorvid) | Systemic Lupus Erythematosus (SLE) | Activation of the TLR/MyD88/NF-κB signaling pathway regulates pro-inflammatory cytokines and autoimmunity. | Preclinical |
| Oligonucleotide inhibitors (e.g., 1018) | Atherosclerosis (AS) | TLR4/MyD88 signaling drives inflammation, promoting the progression of atherosclerotic plaques. | Preclinical |
| JAK inhibitors (e.g., Tofacitinib) | Rheumatoid Arthritis (RA) | TLR2 and TLR4 activate MyD88-dependent NF-κB signaling, enhancing inflammatory cytokine production in synovial tissue. | Preclinical |
| OX-1 (TLR9 antagonist) | Ulcerative Colitis (UC) | MyD88 activation through TLR2, TLR4, and TLR9 induces intestinal inflammation via NF-κB signaling. | Preclinical |
| BAY-11-7082 | Alzheimer's Disease (AD) | MyD88/NF-κB activation is linked to neuroinflammation and may play a role in AD pathogenesis. | Preclinical |
| Resatorvid (TAK-242) | Parkinson's Disease (PD) | Dysregulated TLR/MyD88 signaling contributes to neuroinflammation and neuronal damage in PD. | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers assistance on the research and development of therapies designed to target MyD88 pathway. Considering the specialized knowledge in the area of MyD88 signaling and its intricate mechanisms, our team is well prepared for the unique difficulties of targeting such pathway. We offer customized strategies that expedite the realization and creation of those therapeutics which are new and innovative that tackle these diseases effectively with a considerate and well planned method.
Featured Therapeutics Discovery Services
Within the therapeutic discovery services area, Protheragen's featured services complement the work of the clientele by facilitating the development and assisting modernization with the use of advanced platforms, as well as modified strategies. We are experienced in developing small molecule inhibitors, monoclonal antibodies, siRNA, and mimetic peptides that help constrain sophisticated biological mechanisms efficiently.
Protheragen focuses on developing highly effective and specific small molecule inhibitors targeting specific functional nodes in MyD88 signaling pathways. These inhibitors precisely modulate pathological inflammation and abnormal signaling by blocking protein-protein interactions or enzyme activity.
By utilizing high level antibody engineering, Protheragen has the ability to develop high affinity monoclonal antibodies directed against MyD88 related targets. Our services include antibody screening, functional optimization, and specific immune intervention to ensure therapeutic precision.
Protheragen provides siRNA design and optimization services to specifically silence selective functional genes within the MyD88 signaling pathway. Our modules are designed to maximise targeting accuracy while improving therapeutic effectiveness and safety.
Utilizing mimetic peptide technology, we produce therapeutic peptides that recreate the functional activities of crucial proteins or inhibit excessive protein-protein interactions within the MyD88 signaling pathway and thereby develop novel therapeutic approaches.
Types of MyD88-Targeted Diseases
- Autoimmune Diseases
- Inflammatory Diseases
- Transplant Rejection
- Ischemia-Reperfusion
- Allergic Diseases
- Cancers
- Neurodegenerative
- Metabolic Diseases
Protheragen focuses on providing one-stop services for MyD88-related diseases, including therapeutic discovery, disease model development, pharmacokinetics research, and drug safety evaluation. Additionally, we favorably extend support to investigator-initiated trials (IIT), thereby incentivizing potencies in drug development as well as enhancing therapy innovation.
If you are interested in our services, please don't hesitate to contact us.
References
- Di Padova, F., V. F. J. Quesniaux, and B. Ryffel. "Myd88 as a Therapeutic Target for Inflammatory Lung Diseases." Expert Opinion on Therapeutic Targets 22.5 (2018): 401-08.
- Liu, Y., et al. "Myd88 in Myofibroblasts Enhances Nonalcoholic Fatty Liver Disease-Related Hepatocarcinogenesis Via Promoting Macrophage M2 Polarization." Cell Commun Signal 22.1 (2024): 86.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.